Merck & Co. (MRK)
(Delayed Data from NYSE)
$114.74 USD
+1.18 (1.04%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $114.46 -0.28 (-0.24%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$114.74 USD
+1.18 (1.04%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $114.46 -0.28 (-0.24%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Zacks News
Top Analyst Reports for Merck, Salesforce & Philip Morris
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Salesforce, Inc. (CRM) and Philip Morris International Inc. (PM).
Why the Market Dipped But Merck (MRK) Gained Today
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $114.77, marking a +1.35% move from the previous day.
Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation
by Zacks Equity Research
Bristol Myers' (BMY) repotrectinib is under review in the European Union for the treatment of locally advanced or metastatic ROS1-Positive NSCLC and NTRK-positive solid tumors.
Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday
by Zacks Equity Research
Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.
C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why
by Zacks Equity Research
C4 Therapeutics (CCCC) shares surge on a licensing deal to develop degrader-antibody conjugates with Merck and positive data from CFT7455 studies.
Company News for Jan 3, 2024
by Zacks Equity Research
Companies in The News Are: MRNA, RCL, NVDA, MRK
Why Merck (MRK) Outpaced the Stock Market Today
by Zacks Equity Research
In the most recent trading session, Merck (MRK) closed at $107.98, indicating a +0.33% shift from the previous trading day.
Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority Tag
by Zacks Equity Research
Merck (MRK) and Daiichi Sankyo's regulatory filing for HER3-DXd gets the FDA's priority review grant for the treatment of adult patients with lung cancer. A final decision is expected on Jun 26, 2024.
Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate
by Kinjel Shah
FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.
Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA
by Zacks Equity Research
Per the FDA, the data submitted by Merck (MRK) for its chronic cough drug did not provide sufficient evidence to prove its clinical benefit in patients.
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Merck (MRK) Stock Moves -1.06%: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $105.36, marking a -1.06% move from the previous day.
FDA Accepts Merck's (MRK) BLA for 21-Valent Pneumococcal Jab
by Zacks Equity Research
The FDA grants priority review to Merck's (MRK) filing seeking approval for its 21-valent pneumococcal conjugate vaccine in adults. A final decision is expected in June 2024.
Pfizer (PFE) Stock Rises on FDA Nod for Expanded Use of Padcev
by Zacks Equity Research
The FDA approves Pfizer's (PFE) Padcev in combination with Merck's (MRK) Keytruda for adult patients with advanced bladder cancer. Stock rises 1.6%.
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer
by Zacks Equity Research
Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.
FDA Expands Merck's (MRK) Welireg Label in Renal Cell Carcinoma
by Zacks Equity Research
Per Merck (MRK), the latest FDA approval to Welireg marks the first time a new treatment has been approved in a novel therapeutic class in advanced renal cell carcinoma since 2015.
Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study
by Zacks Equity Research
Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.
NextCure (NXTC) Down on Shelving Plans to Develop Candidate
by Zacks Equity Research
NextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same.
Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More
by Kinjel Shah
Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.
Merck (MRK) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Merck (MRK) concluded the recent trading session at $105.88, signifying a -1.15% move from its prior day's close.
C4 Therapeutics (CCCC) Soars on Oncology Deal With Merck
by Zacks Equity Research
C4 Therapeutics (CCCC) inks an agreement with Merck to discover and develop degrader-antibody conjugates with a focus on one oncology target. Shares rise on the same.
Moderna (MRNA), Merck Start 2nd Late-Study on Cancer Therapy
by Zacks Equity Research
The second late-stage study will evaluate Moderna (MRNA)/Merck's investigational cancer combination therapy in certain lung cancer patients. A late-stage study in melanoma indication is ongoing.
The Zacks Analyst Blog Highlights Merck, Equinor, Illinois Tool Works, Arthur J. Gallagher and Atlassian
by Zacks Equity Research
Merck, Equinor, Illinois Tool Works, Arthur J. Gallagher and Atlassian are part of the Zacks top Analyst Blog.
Top Research Reports for Merck, Equinor & Illinois Tool Works
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Equinor ASA (EQNR) and Illinois Tool Works Inc. (ITW).
Merck's (MRK) Keytruda, Lenvima Endometrial Cancer Study Fails
by Zacks Equity Research
The combination of Merck's (MRK) Keytruda and Eisai's Lenvima for the first-line treatment of advanced/recurrent endometrial carcinoma fails to meet dual primary endpoints in late-stage study.